Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy
Osteoporosis-related fractures are a major public health problem and one in two women and one in four men are affected with osteoporosis-related fractures. Alendronate (Fosamax) is one of the first bisphosphonates used to treat osteoporosis effectively. Recently, however, there is a concern regardin...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Journal of Osteoporosis |
Online Access: | http://dx.doi.org/10.4061/2011/810697 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832567539767443456 |
---|---|
author | Ravindra Gudena Jason Werle Kelly Johnston |
author_facet | Ravindra Gudena Jason Werle Kelly Johnston |
author_sort | Ravindra Gudena |
collection | DOAJ |
description | Osteoporosis-related fractures are a major public health problem and one in two women and one in four men are affected with osteoporosis-related fractures. Alendronate (Fosamax) is one of the first bisphosphonates used to treat osteoporosis effectively. Recently, however, there is a concern regarding long bone insufficiency fractures related to long-term alendronate therapy. We report a case of bilateral femoral insufficiency fractures likely related to long-term alendronate therapy, the classic symptoms, signs, and treatment of these fractures. |
format | Article |
id | doaj-art-aa52ee5fa6664db698504519f86dc2f6 |
institution | Kabale University |
issn | 2042-0064 |
language | English |
publishDate | 2011-01-01 |
publisher | Wiley |
record_format | Article |
series | Journal of Osteoporosis |
spelling | doaj-art-aa52ee5fa6664db698504519f86dc2f62025-02-03T01:01:19ZengWileyJournal of Osteoporosis2042-00642011-01-01201110.4061/2011/810697810697Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate TherapyRavindra Gudena0Jason Werle1Kelly Johnston2Department of Orthopedics, University of Calgary, 711B, 3607-49 ST NW, Calgary, Alberta, T3A 2H3, CanadaDepartment of Orthopedics, University of Calgary, 711B, 3607-49 ST NW, Calgary, Alberta, T3A 2H3, CanadaDepartment of Orthopedics, University of Calgary, 711B, 3607-49 ST NW, Calgary, Alberta, T3A 2H3, CanadaOsteoporosis-related fractures are a major public health problem and one in two women and one in four men are affected with osteoporosis-related fractures. Alendronate (Fosamax) is one of the first bisphosphonates used to treat osteoporosis effectively. Recently, however, there is a concern regarding long bone insufficiency fractures related to long-term alendronate therapy. We report a case of bilateral femoral insufficiency fractures likely related to long-term alendronate therapy, the classic symptoms, signs, and treatment of these fractures.http://dx.doi.org/10.4061/2011/810697 |
spellingShingle | Ravindra Gudena Jason Werle Kelly Johnston Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy Journal of Osteoporosis |
title | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy |
title_full | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy |
title_fullStr | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy |
title_full_unstemmed | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy |
title_short | Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy |
title_sort | bilateral femoral insufficiency fractures likely related to long term alendronate therapy |
url | http://dx.doi.org/10.4061/2011/810697 |
work_keys_str_mv | AT ravindragudena bilateralfemoralinsufficiencyfractureslikelyrelatedtolongtermalendronatetherapy AT jasonwerle bilateralfemoralinsufficiencyfractureslikelyrelatedtolongtermalendronatetherapy AT kellyjohnston bilateralfemoralinsufficiencyfractureslikelyrelatedtolongtermalendronatetherapy |